Ionis Pharmaceuticals Inc (IONS)
40.80
+0.16
(+0.38%)
USD |
NASDAQ |
Jun 17, 14:09
Ionis Pharmaceuticals SG&A Expense (Annual): 232.60M for Dec. 31, 2023
SG&A Expense (Annual) Chart
Historical SG&A Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2023 | 232.60M |
| December 31, 2022 | 150.30M |
| December 31, 2021 | 170.90M |
| December 31, 2020 | 332.20M |
| December 31, 2019 | 286.64M |
| December 31, 2018 | 244.62M |
| December 31, 2017 | 108.49M |
| December 31, 2016 | 48.62M |
| December 31, 2015 | 37.17M |
| December 31, 2014 | 20.14M |
| December 31, 2013 | 14.92M |
| December 31, 2012 | 12.52M |
| December 31, 2011 | 12.79M |
| December 31, 2010 | 11.67M |
| December 31, 2009 | 14.52M |
| December 31, 2008 | 13.81M |
| December 31, 2007 | 13.06M |
| Date | Value |
|---|---|
| December 31, 2006 | 11.20M |
| December 31, 2005 | 7.888M |
| December 31, 2004 | 9.576M |
| December 31, 2003 | 10.20M |
| December 31, 2002 | 5.545M |
| December 31, 2001 | 15.63M |
| December 31, 2000 | 9.231M |
| December 31, 1999 | 10.60M |
| December 31, 1998 | 9.50M |
| December 31, 1997 | 8.10M |
| December 31, 1996 | 51.80M |
| December 31, 1995 | 5.40M |
| December 31, 1994 | 6.00M |
| December 31, 1993 | 4.80M |
| December 31, 1992 | 30.30M |
| December 31, 1991 | 4.40M |
| December 31, 1990 | 1.70M |
SG&A Expense Definition
SG&A expense (short for Selling, General and Administrative expense) is a line item on the income statement, though sometimes sales and marketing expenses are reported separately from general and administrative expenses.
SG&A Expense (Annual) Range, Past 5 Years
150.30M
Minimum
2022
332.20M
Maximum
2020
234.53M
Average
232.60M
Median
2023
SG&A Expense (Annual) Benchmarks
| Biogen Inc | 2.550B |
| Madrigal Pharmaceuticals Inc | 108.15M |
| Viking Therapeutics Inc | 37.02M |
| Alnylam Pharmaceuticals Inc | 795.65M |
| United Therapeutics Corp | 477.10M |